Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.44 |
| ▸ | DRD3 | P35462 | 8/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.38 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.38 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.38 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16412900 | 0.81 | DRD2 (0.50) | DRD2DRD3CYP19A1LDHAABCC9 | |
| SCHEMBL6540021 | 0.81 | DRD2 (0.50) | DRD2DRD3CYP19A1LDHAABCC9 | |
| SCHEMBL4378996 | 0.81 | DRD2 (0.50) | DRD2DRD3CYP19A1LDHAABCC9 | |
| SCHEMBL29813085 | 0.81 | DRD2 (0.50) | DRD2DRD3CYP19A1LDHAABCC9 | |
| SCHEMBL31332598 | 0.78 | DRD2 (0.51) | DRD2DRD3CYP19A1LDHAABCC9 | |
| SCHEMBL4697431 | 0.77 | DRD2 (0.44) | DRD2DRD3CYP19A1ABCC9ABCC8 | |
| SCHEMBL27988042 | 0.77 | KDM1A (0.43) | DRD2DRD3KDM1A | |
| SCHEMBL4259825 | 0.75 | TSHR (0.54) | CYP19A1TSHRMAOAMAOB | |
| SCHEMBL4699085 | 0.74 | DRD2 (0.51) | DRD2DRD3CYP19A1ABCC9ABCC8 | |
| SCHEMBL4697941 | 0.74 | DRD2 (0.44) | DRD2DRD3CYP19A1LDHAABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007047306-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | APP, DNPEP, ASPH | DRD2 4859/4885DRD3 4828/4885CYP19A1 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.